Trials / Unknown
UnknownNCT03203980
Bleeding Events After Triple Antithrombotic Therapy Initiation.
Bleeding Events After Triple Antithrombotic Therapy Initiation: a Prospective Observational Study in Real Life
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard. Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Triple antithrombotic therapy | patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA) |
Timeline
- Start date
- 2017-07-15
- Primary completion
- 2018-01-15
- Completion
- 2018-07-15
- First posted
- 2017-06-29
- Last updated
- 2017-07-11
Source: ClinicalTrials.gov record NCT03203980. Inclusion in this directory is not an endorsement.